Janssen Oncology Strategy: Take A Holistic Approach To R&D

With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.

Johnson & Johnsonchalks up its recent oncology successes to increased R&D investment and a comprehensive, focused oncology strategy in particular disease areas – with hematological malignancies as a top target.

The company had a history in oncology with products like Doxil (doxorubicin) and Procrit (epoetin alfa) and the proteasome inhibitor...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip